News
2023.12.05
AI project centered on managing director Lee Kyung-ik, a modeling expert for new drugs
Digital transformation and commercialization of clinical genomic analysis data
Dx&Vx announced on the 5th that it is working on an AI-based new drug development project centered on Lee Kyung-ik (Physical Chemistry Doctor), a new drug modeling expert.
A former senior researcher at Hanmi Pharmaceutical, Lee Kyung-ik, who recently joined the New Drug Research Headquarters, is a new drug development expert based on AI modeling who has experience in all areas of research, from structure to calculation and synthesis. He has expertise and know-how in designing real molecules through various experiences such as chemical synthesis and protein expression.
In particular, he laid the foundation for Korea's improved new drug business with the development of amlodipine camcilate, an ingredient in high blood pressure treatment. Amlodipine camcilate is an improved new drug that changed the chemical structure of the original pharmaceutical company Novask's amlodipine bacilate, and the advantage is that it can reduce manufacturing costs to less than 50% by increasing the response rate more than twice compared to the existing amlodipine synthesis method.
Through computer-aided drug design (CADD), the company has optimized various synthetic new drugs and contributed significantly to the development of 5-prime-capping (5′-capping) and lipid nanoparticle (LNP) processes, which are key technologies for the development of messenger ribonucleic acid (mRNA) based vaccines and therapeutics. Youngjin Pharmaceutical also made achievements in the areas of treatments for rare diseases and anticancer drugs.
With managing director Lee Kyung-ik at the center, Dx&Vx is actively promoting innovative new projects as well as optimizing new drug candidates using AI.
Recently, by recruiting Song Ki-young, an IT expert with more than 20 years of experience, as the head of the IT planning team, he is in the process of digital transformation and commercialization of Dx&Vx 's medical data assets. Song has a wealth of practical experience, such as serving as the head of Nexon's Chinese subsidiary and promoting AI-based medical software planning at Tencent, and has formed a group of IT experts such as front and backend developers to lead Dx&Vx 's digital transformation.
Dx&Vx plans to soon release a service for upgrading and commercializing a medical information platform through the transformation of an AI-based digital DB system centered on the IT planning team. The medical information platform will be expanded to a B2B service aimed at new drug developers and hospitals that need specific dielectric information. Dx&Vx has more than 400,000 clinical genome analysis data, the largest in Korea.
AI-based services are also becoming a new trend in the medical market, a Dx&Vx official said. "We are currently operating various new drug development projects and will use artificial intelligence (AI) in each area to increase the likelihood of success in new drug development while expanding related services."
Meanwhile, Dx&Vx participating in clinical trials to develop new drugs for metabolic diseases such as obesity and diabetes at its affiliates Coree Italy and Gemelli Hospital, and is promoting various new drug development projects such as license-in review of Oxford BackMedics' anti-cancer vaccine "OVM-200," a pipeline related to ophthalmic diseases, and the development of anti-cancer antibody vaccines and treatments through an organization dedicated to new drug development.
Source: Bizwatch